Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Share-based Compensation (2016 - 2025)

Conmed (CNMD) has disclosed Share-based Compensation for 16 consecutive years, with $5.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation fell 20.63% year-over-year to $5.0 million, compared with a TTM value of $28.3 million through Dec 2025, up 10.64%, and an annual FY2025 reading of $28.3 million, up 10.64% over the prior year.
  • Share-based Compensation was $5.0 million for Q4 2025 at Conmed, up from $4.6 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $13.9 million in Q1 2025 and bottomed at $3.4 million in Q1 2021.
  • Average Share-based Compensation over 5 years is $5.8 million, with a median of $5.8 million recorded in 2022.
  • Peak annual rise in Share-based Compensation hit 122.16% in 2025, while the deepest fall reached 29.7% in 2025.
  • Year by year, Share-based Compensation stood at $4.3 million in 2021, then soared by 32.89% to $5.8 million in 2022, then rose by 3.63% to $6.0 million in 2023, then rose by 4.99% to $6.3 million in 2024, then dropped by 20.63% to $5.0 million in 2025.
  • Business Quant data shows Share-based Compensation for CNMD at $5.0 million in Q4 2025, $4.6 million in Q3 2025, and $4.9 million in Q2 2025.